Table of Contents Table of Contents
Previous Page  587 / 1578 Next Page
Information
Show Menu
Previous Page 587 / 1578 Next Page
Page Background

Dose in relation to volume: OARs

Adebahr S et al. BJR 2015, EORTC Lungtech trial

* Following Mangona, IJROBP 91(1) p124-132 2015, William Beaumont Hospital

OAR

αβ

i n G y

D

max

in Gy

EqD2

in Gy

Acceptable

variation

in Gy

Unacceptable

variation

in Gy

Unacceptable

variation

EqD2 in Gy

Trachea/ MainBronchus

3

8*5.5= 44

74.8

<8*5.81=46.68

≥8*5.81=46.68

≥81.9

Heart

§

3

GreatVessels

§

3

Esophagus

3

8*5 = 40

64

<8*5.44=43.52

≥8*5.44=43.52

≥73.6

SpinalCord

&

2

8*4= 32

48

>8*4=32

≥48

BrachialPlexus

&

3

8*4.75=38

58.9

<8*5.17=41.36

≥8*5.17=41.36

≥ 67.7

External-PTV

&

3

8*7.5= 60

126

<8*7.785=62.28

≥8*7.785=62.28

≥134.2

Lungs-CTV

§

3

ChestWall

§

3

&

for <0.5 cc

§ no restrictions are provided but recording of DVH data for toxicity evaluation is required

EORTC 22113-0813-LungTech RTQA Guidelines

i

y

l

i i

i

t le

i ti

i

c e t le

ri ti

i y

.

.

.

.

.

.

t

*

8*5.5= 44

74.8

<8*6=48

≥8*6=48

≥86.4

t e sels

*

8*5.5= 44

74.8

<8*6=48

≥8*6=48

≥86.4

.

.

.

.

.

.

.

.

.

.

6 .

.

.

.

.

.

-

*

V20Gy<6%

V20<10%

V20Gy≥10%

l

§

8*8.25=66

148.5

≥8*9=72

≥172.8

t t i it

l ti is r ir

Catharina Cancer Centre guidelines